Hormonal therapy and radiation therapy in prostate cancer: 5-year outcomes from a trial evaluating combined androgen blockade with 5-alpha reductase inhibitors as an alternative to gonadotropin releasing hormone agonists
Clinical Genitourinary Cancer(2024)
摘要
Background
We previously reported that for men undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT) for prostate cancer, substitution of LHRH-agonists with 5-α- reductase inhibitors (5-ARIs) led to improved preservation of 6-month hormonal quality of life (hQOL). With longer term follow-up, we evaluated disease control.
Methods
In this non-randomized trial, men with unfavorable intermediate or high-risk prostate cancer, aged ≥70 years or with Charlson Comorbidity Index ≥2, were treated with RT (78-79.2 Gy in 39-44 fractions) and either oral ADT (oADT; 5-ARI with antiandrogen) or standard of care ADT (SOC; leuprolide with antiandrogen) for up to 28 months. The primary endpoint was EPIC hQOL; secondary endpoints included biochemical control and survival as well as changes in cholesterol and hemoglobin levels.
Results
Between 2011-2018, 70 men were enrolled (40 in oADT; 30 in SOC). Median follow-up was 65 months [IQR 36-94]. Five-year freedom from biochemical failure for oADT and SOC was 89% versus 86%, disease free survival was 62% versus 69%, cancer-specific survival was 100% versus 96%, and overall survival was 70% versus 81% (all P>0.1). Testosterone (2 mo through 3 yr) and hemoglobin levels (2 mo through 2 yr) were higher, and cholesterol levels (1 yr) were lower in the oADT groups (all P<0.05).
Conclusions
In this non-randomized study, men treated with combined RT and oADT had better preservation of hQOL and comparable 5-year disease outcomes to men treated with SOC. Eugonadal testosterone with this approach may yield measurable benefits in cholesterol and hemoglobin levels.
Microabstract
We investigated the role of 5α-reductase inhibitors (5-ARIs) as an alternative to LHRH-agonists in this non-randomized trial of men with unfavorable intermediate/high-risk prostate cancer. Men treated with 5-ARIs had better preservation of hormonal quality of life with no obvious detriment in biochemical outcomes with 5 years of follow-up. This approach may be beneficial in men at high risk of toxicities.
更多查看译文
关键词
intermediate/high risk prostate cancer,biochemical outcomes,testosterone,quality of life,androgen deprivation therapy (ADT)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要